Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Cyclopharm.
RELATED STOCKHEAD STORIES
Health & Biotech
Alive and Kicking: Noxopharm has difficult brain cancer in its sights
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
The next Neuren? These ASX biotech stocks have pending FDA catalysts in 2024
Health & Biotech
ASX Health Stocks: Neuren Pharma to begin Phase 2 clinical trial of children with Pitt Hopkins syndrome
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall but Dimerix up 150% on drug licensing deal
News
Market Highlights: ASX Futures down after a wild weekend in Washington, and 5 ASX small caps to watch today
News
CLOSING BELL: CBA makes bank from rising rates, then issues a warning about mortgage arrears
Health & Biotech
ASX Health Stocks: Cyclopharm confident after US FDA inspection; Anteris a step closer to FDA approval
Health & Biotech
These were the best ASX biotechs as Health Care sprang back to life in FY23
Experts
CRITERION: This ASX biotech is the sole dedicated player in a new $420 billion market
Health & Biotech
ASX Health Stocks: The US FDA will pay a visit to Cyclopharm’s facility in NSW
News
Market Highlights: Markets brace for more headwinds, and 5 ASX small caps to watch on Tuesday
Health & Biotech
ASX Health Stocks: Cyclopharm sends reply to FDA, the final step before potential approval
News
Market highlights and 5 ASX small caps to watch on Wednesday
Health & Biotech
ASX Health Stocks: FDA to expedite submission for Botanix’s sweaty armpits gel
Health & Biotech
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
Health & Biotech
